(Q27027319)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24142092%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

title

Mild cognitive impairment. Part 2: Biological markers for diagnosis and prediction of dementia in Alzheimer's disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24142092%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference

0 references

mild cognitive impairment

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24142092%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Antonio L Teixeira

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24142092%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

5

Wagner Gattaz

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24142092%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

author name string

Florindo Stella

series ordinal

4

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24142092%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Orestes V Forlenza

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24142092%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

language of work or name

1 reference

1 July 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24142092%20AND%20SRC:MED&resulttype=core&format=json

Brazilian Journal of Psychiatry

28 February 2020

published in

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24142092%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

volume

35

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24142092%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

issue

3

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24142092%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

page(s)

284-294

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24142092%20AND%20SRC:MED&resulttype=core&format=json

Forecasting the global burden of Alzheimer’s disease

28 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Diagnosis and biomarkers of predementia in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Mild cognitive impairment: clinical characterization and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Molecular mechanism of Alzheimer's neurofibrillary degeneration and therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

The molecular pathology of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Alzheimer's disease: the amyloid cascade hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Pathways towards and away from Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Cerebrospinal fluid protein biomarkers for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

The clinical use of structural MRI in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Consensus paper of the WFSBP Task Force on Biological Markers of Dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

CSF markers for incipient Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Cerebrospinal fluid biochemical markers in early detection and in differential diagnosis of dementia disorders in routine clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

CSF phosphorylated tau protein and mild cognitive impairment: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Clinical and biological predictors of Alzheimer's disease in patients with amnestic mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Do CSF total tau, phosphorylated tau, and beta-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer's disease? A systematic review and meta-analysis of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease: a meta-analysis of 51 studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Episodic memory and speed/attention deficits are associated with Alzheimer-typical CSF abnormalities in MCI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Profiles of functional deficits in mild cognitive impairment and dementia: benefits from objective measurement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Plasma levels of amyloid beta-protein 42 are increased in women with mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Brain-derived neurotrophic factor and Alzheimer's disease: physiopathology and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Circulating levels of brain-derived neurotrophic factor: correlation with mood, cognition and motor function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

New insights into brain BDNF function in normal aging and Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Neuropathology and the neuroinflammation idea

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Increased serum IL-1beta level in Alzheimer's disease and mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Inflammatory markers and the risk of Alzheimer disease: the Framingham Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Intrathecal inflammation precedes development of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Soluble TNF receptors are associated with Aβ metabolism and conversion to dementia in subjects with mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Higher serum sTNFR1 level predicts conversion from mild cognitive impairment to Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Serum BDNF, TNF-alpha and IL-1beta levels in dementia patients: comparison between Alzheimer's disease and vascular dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Effect of brain-derived neurotrophic factor Val66Met polymorphism and serum levels on the progression of mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Effect of the brain-derived neurotrophic factor and the apolipoprotein E polymorphisms on disease progression in preclinical Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Interleukin-1beta serum levels is increased in antidepressant-free elderly depressed patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Serum brain-derived neurotrophic factor level is reduced in antidepressant-free patients with late-life depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Increased soluble TNF receptor 2 in antidepressant-free patients with late-life depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Increased plasma levels of brain-derived neurotrophic factor in patients with long-term bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Serum levels of brain-derived neurotrophic factor correlate with motor impairment in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Platelet amyloid precursor protein processing: a bio-marker for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Abnormalities in the pattern of platelet amyloid precursor protein forms in patients with mild cognitive impairment and Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Abnormal APP processing in platelets of patients with Alzheimer's disease: correlations with membrane fluidity and cognitive decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Reduced platelet amyloid precursor protein ratio (APP ratio) predicts conversion from mild cognitive impairment to Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

The GSK3 hypothesis of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Increased platelet GSK3B activity in patients with mild cognitive impairment and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Platelet GSK3B activity in patients with late-life depression: marker of depressive episode severity and cognitive impairment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Voxel-based morphometry in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Neuroimaging in Alzheimer disease: an evidence-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

3D comparison of hippocampal atrophy in amnestic mild cognitive impairment and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Cortical thickness in single- versus multiple-domain amnestic mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Spatial patterns of cortical thinning in mild cognitive impairment and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Using voxel-based morphometry to map the structural changes associated with rapid conversion in MCI: a longitudinal MRI study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Longitudinal progression of Alzheimer's-like patterns of atrophy in normal older adults: the SPARE-AD index

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

MRI of hippocampus and entorhinal cortex in mild cognitive impairment: a follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Neurostructural predictors of Alzheimer's disease: a meta-analysis of VBM studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

HMPAO SPET and FDG PET in Alzheimer's disease and vascular dementia: comparison of perfusion and metabolic pattern.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Principal component analysis of FDG PET in amnestic MCI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/PET).

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

PET of brain amyloid and tau in mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Imaging beta-amyloid burden in aging and dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

PET imaging of amyloid deposition in patients with mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Frequent amyloid deposition without significant cognitive impairment among the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Beta-amyloid burden is not associated with rates of brain atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Extreme cerebrospinal fluid amyloid beta levels identify family with late-onset Alzheimer's disease presenilin 1 mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Clinical and biomarker changes in dominantly inherited Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Systemic inflammation induces acute behavioral and cognitive changes and accelerates neurodegenerative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Is aging part of Alzheimer's disease, or is Alzheimer's disease part of aging?

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

The Alzheimer's disease mitochondrial cascade hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Biomarkers for Alzheimer's disease therapeutic trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

International quality control survey of neurochemical dementia diagnostics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Safety and efficacy of galantamine in subjects with mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Vitamin E and donepezil for the treatment of mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

To treat or not to treat? A meta-analysis of the use of cholinesterase inhibitors in mild cognitive impairment for delaying progression to Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Alzheimer's disease: strategies for disease modification

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

A randomized, double-blind, placebo controlled-trial of triflusal in mild cognitive impairment: the TRIMCI study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Endpoints for trials in Alzheimer's disease: a European task force consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

Disease-modifying trials in Alzheimer's disease: a European task force consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2F1516-4446-2012-3505

10.1590/1516-4446-2012-3505

21 January 2018

Identifiers

DOI

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24142092%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24142092%20AND%20SRC:MED&resulttype=core&format=json